Novartis long-term Phase III data show Ph+ CML patients on Tasigna® achieved significantly deeper molecular response versus Glivec®
17:31 EST 10 Dec 2012 | Thomson Reuters
This article has expired, however you can still
download the PDF.
Preview:
Novartis International AG /
Novartis long-term Phase III data show Ph+ CML patients on Tasigna® achieved
significantly deeper molecular response versus Glivec®
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the...
Other Sources for this Article
More From BioPortfolio on "Novartis long-term Phase III data show Ph+ CML patients on Tasigna® achieved significantly deeper molecular response versus Glivec®"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
